Literature DB >> 17187598

Eosinophil activation in preterm infants with lung disease.

E Berggren Broström1, M Katz-Salamon, J Lundahl, G Halldén, B Winbladh.   

Abstract

AIM: We investigated the role of eosinophils in the pathogenesis of bronchopulmonary dysplasia (BPD) in preterm infants.
METHODS: Fifteen preterm infants with BPD were compared to 13 preterms with respiratory distress syndrome (RDS) and to 16 healthy preterms. We assessed total eosinophil and neutrophil counts in venous blood samples and the levels of the eosinophilic activity markers eosinophilic cationic protein (ECP) and the cellular surface antigen (CD9).
RESULTS: The eosinophil count was greater in BPD compared with RDS and healthy infants (1414 vs. 797 and 471 cells per microlitre, respectively, p = 0.03). ECP levels were elevated (34 vs. 12.8 and 9.8 microg/L, respectively, p = 0.002) and CD9 levels reduced (75 vs. 94 and 86 mean fluorescence intensity units, respectively, p = 0.01) in BPD compared with RDS and healthy infants, suggesting eosinophilic activation in BPD. These findings were not solely explained by differences between gestational age or birth weight of the different groups. ECP levels were positively correlated with the duration of oxygen supplementation in the BPD group. The eosinophil count fell promptly after steroid treatment was commenced in the BPD group.
CONCLUSION: The findings suggest that BPD is linked to eosinophil activation, which might contribute to the pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187598     DOI: 10.1111/j.1651-2227.2006.00002.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

1.  The relationship between eosinophilia and bronchopulmonary dysplasia in premature infants at less than 34 weeks' gestation.

Authors:  Joo Yun Yang; Jihei Cha; So-Yeon Shim; Su Jin Cho; Eun Ae Park
Journal:  Korean J Pediatr       Date:  2014-04-30

2.  Increased serum Th2 chemokine levels are associated with bronchopulmonary dysplasia in premature infants.

Authors:  Dan Zhou; Fang Shi; Ying Xiong; Min Zhou; Huajing Wan; Hanmin Liu
Journal:  Eur J Pediatr       Date:  2018-10-15       Impact factor: 3.183

Review 3.  Perinatal oxygen in the developing lung.

Authors:  Elizabeth R Vogel; Rodney D Britt; Mari Charisse Trinidad; Arij Faksh; Richard J Martin; Peter M MacFarlane; Christina M Pabelick; Y S Prakash
Journal:  Can J Physiol Pharmacol       Date:  2014-12-09       Impact factor: 2.273

4.  Neonatal oxygen increases sensitivity to influenza A virus infection in adult mice by suppressing epithelial expression of Ear1.

Authors:  Michael A O'Reilly; Min Yee; Bradley W Buczynski; Peter F Vitiello; Peter C Keng; Stephen L Welle; Jacob N Finkelstein; David A Dean; B Paige Lawrence
Journal:  Am J Pathol       Date:  2012-06-05       Impact factor: 4.307

5.  Perinatal factors in neonatal and pediatric lung diseases.

Authors:  Rodney D Britt; Arij Faksh; Elizabeth Vogel; Richard J Martin; Christina M Pabelick; Y S Prakash
Journal:  Expert Rev Respir Med       Date:  2013-10-03       Impact factor: 3.772

6.  Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model.

Authors:  David K Meyerholz; Michelle A Griffin; Elaine M Castilow; Steven M Varga
Journal:  Toxicol Pathol       Date:  2009-01-29       Impact factor: 1.902

7.  Impact and Clinical Implications of Prematurity on Adaptive Immune Development.

Authors:  Emma Idzikowski; Thomas J Connors
Journal:  Curr Pediatr Rep       Date:  2020-10-26

8.  Serum eotaxin-1 is increased in extremely-low-birth-weight infants with bronchopulmonary dysplasia or death.

Authors:  Jegen Kandasamy; Claire Roane; Alexander Szalai; Namasivayam Ambalavanan
Journal:  Pediatr Res       Date:  2015-08-13       Impact factor: 3.756

9.  Can biomarkers be used to predict bronchopulmonary dysplasia?

Authors:  Vineet Bhandari; Mitali Sahni
Journal:  J Pediatr (Rio J)       Date:  2020-10-23       Impact factor: 2.990

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.